<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Degen D</submitter><funding>Howard Hughes Medical Institute</funding><funding>NIAID NIH HHS</funding><funding>National Institutes of Health</funding><funding>NIGMS NIH HHS</funding><pagination>e02451</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC4029172</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>3</volume><pubmed_abstract>We report that bacterial RNA polymerase (RNAP) is the functional cellular target of the depsipeptide antibiotic salinamide A (Sal), and we report that Sal inhibits RNAP through a novel binding site and mechanism. We show that Sal inhibits RNA synthesis in cells and that mutations that confer Sal-resistance map to RNAP genes. We show that Sal interacts with the RNAP active-center 'bridge-helix cap' comprising the 'bridge-helix N-terminal hinge', 'F-loop', and 'link region'. We show that Sal inhibits nucleotide addition in transcription initiation and elongation. We present a crystal structure that defines interactions between Sal and RNAP and effects of Sal on RNAP conformation. We propose that Sal functions by binding to the RNAP bridge-helix cap and preventing conformational changes of th</pubmed_abstract><journal>eLife</journal><pubmed_title>Transcription inhibition by the depsipeptide antibiotic salinamide A.</pubmed_title><pmcid>PMC4029172</pmcid><funding_grant_id>GM084350</funding_grant_id><funding_grant_id>R01 AI104660</funding_grant_id><funding_grant_id>P41 GM111244</funding_grant_id><funding_grant_id>GM041376</funding_grant_id><funding_grant_id>P41 GM103485</funding_grant_id><funding_grant_id>R01 GM084350</funding_grant_id><funding_grant_id>R01 GM041376</funding_grant_id><funding_grant_id>R01 AI072766</funding_grant_id><funding_grant_id>AI072766</funding_grant_id><funding_grant_id>R37 GM041376</funding_grant_id><funding_grant_id>AI104660</funding_grant_id><pubmed_authors>Fenical W</pubmed_authors><pubmed_authors>Feng Y</pubmed_authors><pubmed_authors>Talaue M</pubmed_authors><pubmed_authors>Ebright KY</pubmed_authors><pubmed_authors>Gigliotti M</pubmed_authors><pubmed_authors>Degen D</pubmed_authors><pubmed_authors>Mandal S</pubmed_authors><pubmed_authors>Ebright RH</pubmed_authors><pubmed_authors>Zhang Y</pubmed_authors><pubmed_authors>Connell N</pubmed_authors><pubmed_authors>Vahedian-Movahed H</pubmed_authors><pubmed_authors>Arnold E</pubmed_authors><pubmed_authors>Ebright YW</pubmed_authors></additional><is_claimable>false</is_claimable><name>Transcription inhibition by the depsipeptide antibiotic salinamide A.</name><description>We report that bacterial RNA polymerase (RNAP) is the functional cellular target of the depsipeptide antibiotic salinamide A (Sal), and we report that Sal inhibits RNAP through a novel binding site and mechanism. We show that Sal inhibits RNA synthesis in cells and that mutations that confer Sal-resistance map to RNAP genes. We show that Sal interacts with the RNAP active-center 'bridge-helix cap' comprising the 'bridge-helix N-terminal hinge', 'F-loop', and 'link region'. We show that Sal inhibits nucleotide addition in transcription initiation and elongation. We present a crystal structure that defines interactions between Sal and RNAP and effects of Sal on RNAP conformation. We propose that Sal functions by binding to the RNAP bridge-helix cap and preventing conformational changes of th</description><dates><release>2014-01-01T00:00:00Z</release><publication>2014 Apr</publication><modification>2026-05-01T23:14:22.947Z</modification><creation>2019-03-27T00:14:29Z</creation></dates><accession>S-EPMC4029172</accession><cross_references><pubmed>24843001</pubmed><doi>10.7554/eLife.02451</doi></cross_references></HashMap>